OVERVIEW
Farxiga, Invokana, and Jardiance are sodium glucose co-transporter-2 (SGLT-2) inhibitors indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. SGLT-2 is expressed in the proximal renal tubules, and is responsible for the majority of reabsorption of filtered glucose from the tubular lumen. By inhibiting SGLT-2, Farxiga, Invokana, and Jardiance reduce the reabsorption of filtered glucose and lower the renal threshold for glucose, thereby increasing urinary glucose excretion. Xigduo XR, Synjardy, Synjardy XR, Invokamet, and Invokamet XR are combination products containing an SGLT-2 inhibitor and metformin extended-release or metformin.

POLICY STATEMENT
A step therapy program has been developed to encourage the use of a Step 1 product prior to the use of a Step 2 product. If the step therapy rule is not met for a Step 2 agent at the point of service, coverage will be determined by the step therapy criteria below. All approvals are provided for 12 months in duration.

Automation: Patients with a history of one Step 1 drug within the 130-day look-back period are excluded from step therapy.

Step 1: metformin, metformin-extended release, Fortamet ER, Glucophage, Glucophage XR, Glumetza ER, Riomet solution, Glucovance, glyburide-metformin, glipizide-metformin, ActoplusMet, pioglitazone-metformin, Actoplus Met XR, Avandamet, Prandimet, repaglinide/metformin, Kazano, alogliptin/metformin, Jentadueto, Kombiglyze XR, Janumet, Janumet XR.

Step 2: Farxiga, Invokana, Invokamet, Invokamet XR, Jardiance, Xigduo XR, Synjardy, Synjardy XR

CRITERIA
1. If the patient has tried one Step 1 product, authorization for a Step 2 product may be given.

2. If the patient will be initiating dual-therapy with metformin AND a single-entity Step 2 sodium glucose co-transporter-2 (SGLT-2) inhibitor, approve a single-entity Step 2 SGLT-2 inhibitor.

3. If the patient has been started on a Step 2 agent, approve the Step 2 product (patients are not required to go back and try a Step 1 product).

4. No other exceptions are recommended.
References

- Jardiance® tablets [prescribing information]. Ridgefield, CT and Indianapolis, IN: Boehringer Ingelheim Pharmaceuticals, Inc and Eli Lilly and Company; August 2014.
- Invokamet™ tablets [prescribing information]. Titusville, NJ: Janssen; August 2014.
- Xigduo XR tablets [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2014.
- Synjardy® tablets [prescribing information]. Ridgefield, CT and Indianapolis, IN: Boehringer Ingelheim Pharmaceuticals, Inc and Eli Lilly and Company; August 2015.
- Synjardy XR® tablets [prescribing information]. Ridgefield, CT and Indianapolis, IN: Boehringer Ingelheim Pharmaceuticals, Inc and Eli Lilly and Company; December 2016.